Anthony @ Equity Investigations, Dear Anthony, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony,

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: GregS who wrote (35973)	5/13/1999 5:52:00 PM
From: ACS_101	Read Replies (1) of 122087

Anyone spot the connection between IMCL and MATX? MATX's drug is a cisplatin in a gel form that concentrates the drug's effect on the tumor being treated. IMCL's lead drug C225, is being Phase III tested in combination therapy with cisplatin, compared to cisplatin alone. I am no doctor, but these approaches sound as likely to be complimentary as competitive. IOW, maybe MATX's drug plus C225 is a better combination therapy than cisplatin.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next